title: Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody.
abstract: Recently observations of rhabdomyolysis in patients treated with tacrolimus have been reported. The authors present a kidney transplant patient who had an epileptic seizures, severe rhabdomyolysis, and acute renal failure. The patient was initially immunosuppressed with tacrolimus and chimeric CD25 monoclonal antibody. After intensive therapy with plasmapheresis, CVVH, and dialysis, the patient completely recovered at 11/2 year his serum creatinine is 1.2 mg/dL.
authors.affiliation: Department of Transplantation, San Martino University Hospital, Genoa, Italy. iris.fontana@hsanmartino.liguria.it
authors.forename: I
authors.initials: I
authors.lastname: Fontana
authors.forename: F
authors.initials: F
authors.lastname: Ginevri
authors.forename: G
authors.initials: G
authors.lastname: Basile
authors.forename: M
authors.initials: M
authors.lastname: Beatini
authors.forename: M
authors.initials: M
authors.lastname: Bertocchi
authors.forename: L
authors.initials: L
authors.lastname: Bonifazio
authors.forename: L
authors.initials: L
authors.lastname: Saltalamacchia
authors.forename: D
authors.initials: D
authors.lastname: Ghinolfi
authors.forename: G
authors.initials: G
authors.lastname: Santori
authors.forename: R
authors.initials: R
authors.lastname: Valente
authors.forename: F
authors.initials: F
authors.lastname: Perfumo
authors.forename: U
authors.initials: U
authors.lastname: Valente
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D006435:Renal Dialysis; D012206:Rhabdomyolysis / Q000139:chemically induced*; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D020123:Sirolimus; D016559:Tacrolimus